1. Home
  2. LICN vs DVAX Comparison

LICN vs DVAX Comparison

Compare LICN & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lichen China Limited

LICN

Lichen China Limited

N/A

Current Price

$3.06

Market Cap

47.5M

Sector

N/A

ML Signal

N/A

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$15.44

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LICN
DVAX
Founded
2004
1996
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.5M
1.3B
IPO Year
2023
2004

Fundamental Metrics

Financial Performance
Metric
LICN
DVAX
Price
$3.06
$15.44
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$26.50
AVG Volume (30 Days)
63.3K
4.3M
Earning Date
12-19-2025
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,641,000.00
$330,514,000.00
Revenue This Year
N/A
$24.63
Revenue Next Year
N/A
$15.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
26.73
52 Week Low
$2.57
$9.20
52 Week High
$40.00
$15.49

Technical Indicators

Market Signals
Indicator
LICN
DVAX
Relative Strength Index (RSI) 47.26 89.03
Support Level $2.80 $10.78
Resistance Level $3.11 $15.43
Average True Range (ATR) 0.20 0.14
MACD -0.00 0.34
Stochastic Oscillator 27.13 98.97

Price Performance

Historical Comparison
LICN
DVAX

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: